4 citations
,
August 2021 in “Annals of Translational Medicine” In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.
2 citations
,
January 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that androgen signaling can inhibit Wnt-stimulated growth in prostate basal cell organoids, suggesting a key role in regulating their multipotency.
April 2018 in “The Journal of Urology” This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.
50 citations
,
April 2010 in “Biology direct” This study's model suggests that low androgen levels can increase selection for prostate cancer phenotypes resistant to hormonal therapy, potentially leading to more aggressive forms of cancer.
August 2023 in “Malaysian Journal of Medicine and Health Sciences/Malaysian journal of medicine and health sciences” This study found that aqueous extract of Pueraria mirifica, when administered to a rat model, significantly reduced prostate weight, prostatic index, and serum dihydrotestosterone levels, while also improving prostate histomorphology, suggesting its potential as an anti-BPH treatment.